[go: up one dir, main page]

MX2019008331A - Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. - Google Patents

Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.

Info

Publication number
MX2019008331A
MX2019008331A MX2019008331A MX2019008331A MX2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
pharmaceutical use
janus kinase
novel amino
compounds
Prior art date
Application number
MX2019008331A
Other languages
English (en)
Other versions
MX389378B (es
Inventor
Larsen Mogens
Kyhn Rasmussen Lars
Marianne Duus Tine
Larsen Jens
Ritzen Andreas
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MX2019008331A publication Critical patent/MX2019008331A/es
Publication of MX389378B publication Critical patent/MX389378B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de acuerdo con la fórmula (I) Ver formula. o sales, hidratos o solvatos farmacéuticamente aceptables de estos; donde R, es alquiloC1, R2 es alquilo C1, R3 es alquilo C2, R4 es hidrógeno, Rs es hidrógeno. La invención se refiere además a los compuestos para uso en terapia, a composiciones farmacéuticas que comprenden los compuestos, a los compuestos para uso en el tratamiento de enfermedades autoinmunitarias y a Intermediarios para la preparación de los compuestos.
MX2019008331A 2017-01-11 2018-01-10 Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. MX389378B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
MX2019008331A true MX2019008331A (es) 2020-01-14
MX389378B MX389378B (es) 2025-03-20

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008331A MX389378B (es) 2017-01-11 2018-01-10 Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.

Country Status (26)

Country Link
US (1) US10703751B2 (es)
EP (1) EP3568396B1 (es)
JP (1) JP7009504B2 (es)
KR (1) KR102548543B1 (es)
CN (1) CN110167938B (es)
AU (1) AU2018208516B2 (es)
CA (1) CA3045567A1 (es)
CY (1) CY1123864T1 (es)
DK (1) DK3568396T3 (es)
ES (1) ES2846741T3 (es)
HR (1) HRP20210095T1 (es)
HU (1) HUE052720T2 (es)
IL (1) IL267829B (es)
LT (1) LT3568396T (es)
MX (1) MX389378B (es)
MY (1) MY195576A (es)
NZ (1) NZ754922A (es)
PL (1) PL3568396T3 (es)
PT (1) PT3568396T (es)
RS (1) RS61317B1 (es)
RU (1) RU2019125177A (es)
SI (1) SI3568396T1 (es)
TW (1) TWI760419B (es)
UA (1) UA123972C2 (es)
WO (1) WO2018130563A1 (es)
ZA (1) ZA201904190B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2922379T3 (es) 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
JP2021528479A (ja) * 2018-07-06 2021-10-21 レオ ファーマ アクティーゼルスカブ ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途
US20220396575A1 (en) * 2019-08-30 2022-12-15 Tsd Life Sciences Co., Ltd. Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
EP4304590A1 (en) 2021-03-11 2024-01-17 Janssen Pharmaceutica NV Lorpucitinib for use in the treatment of jak mediated disorders
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389527B2 (en) * 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
SG10201505997TA (en) * 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
UY34616A (es) 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
SG11201503141TA (en) 2012-11-01 2015-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
MX2015006152A (es) * 2012-11-20 2016-01-20 Genentech Inc Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
CN104098563A (zh) 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
BR112016025427A2 (pt) 2014-04-30 2017-08-15 Incyte Corp processos de preparação de um inibidor de jak1 e formas do mesmo
CN113214278B (zh) 2016-10-03 2022-10-28 杭州高光制药有限公司 新型Jak1选择性抑制剂及其用途
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Also Published As

Publication number Publication date
PL3568396T3 (pl) 2021-05-31
LT3568396T (lt) 2021-02-10
ZA201904190B (en) 2020-10-28
JP2020504186A (ja) 2020-02-06
ES2846741T3 (es) 2021-07-29
CN110167938B (zh) 2024-06-14
SI3568396T1 (sl) 2021-04-30
PT3568396T (pt) 2021-02-09
EP3568396B1 (en) 2020-11-11
BR112019014191A2 (pt) 2020-02-11
AU2018208516A1 (en) 2019-07-11
NZ754922A (en) 2025-11-28
IL267829A (en) 2019-09-26
MY195576A (en) 2023-02-02
TWI760419B (zh) 2022-04-11
CN110167938A (zh) 2019-08-23
TW201829407A (zh) 2018-08-16
US10703751B2 (en) 2020-07-07
US20190367512A1 (en) 2019-12-05
DK3568396T3 (da) 2021-01-18
RU2019125177A (ru) 2021-02-15
HRP20210095T1 (hr) 2021-03-05
IL267829B (en) 2022-02-01
WO2018130563A1 (en) 2018-07-19
HUE052720T2 (hu) 2021-05-28
AU2018208516B2 (en) 2021-07-08
KR102548543B1 (ko) 2023-06-29
RU2019125177A3 (es) 2021-05-11
KR20190103231A (ko) 2019-09-04
EP3568396A1 (en) 2019-11-20
CY1123864T1 (el) 2022-05-27
RS61317B1 (sr) 2021-02-26
JP7009504B2 (ja) 2022-01-25
MX389378B (es) 2025-03-20
CA3045567A1 (en) 2018-07-19
UA123972C2 (uk) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
BR112019021853A2 (pt) Compostos de inibidor de vmat2 e composições dos mesmos
UY35535A (es) ?Derivados de fenil sulfonamidas?.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
CO2021003391A2 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
MX2021003871A (es) Inhibidores de pde4 que contienen boro.
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
UY37941A (es) Derivados de bencimidazol y sus usos
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
DOP2025000046A (es) Inhibidores de topoisomerasa-1 derivados de exatecán composiciones farmacéuticas y sus usos
AR035821A1 (es) Composiciones que contienen un compuesto imidazotriazinona y al menos un anestesico local para administracion nasal, el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de la disfuncion erectil masculina , un aplicador de pulverizacion nasal y un insuflador de polvo
UY35536A (es) ?derivados de sulfonamida?.